Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371836 · ClinicalTrials.gov registry record · Phase 4
Use of Clobazam for Epilepsy and Anxiety
A Phase 4 study, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03371836 is a Phase 4 study that has completed, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 20 participants.
The verdict
NCT03371836, a Phase 4 study, has completed, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is an open label, adjunctive, proof of concept, pilot clinical trial. Pediatric patients with epilepsy and clinically significant anxiety will be recruited and if enrolled will receive active treatment, involving flexible dose titration of clobazam and will be monitored for a period of four months. The study will be monitored and overseen by the Johns Hopkins Hospital Institutional Review Board.
Interventions
- DRUG Clobazam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371836
The ClinicalTrials.gov registry entry for NCT03371836 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clobazam is the first listed.
NCT03371836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03371836 about?
NCT03371836 is a clinical study titled "Use of Clobazam for Epilepsy and Anxiety". This study is an open label, adjunctive, proof of concept, pilot clinical trial. Pediatric patients with epilepsy and clinically significant anxiety will be recruited and if enrolled will receive active treatment, involving flexible dose titration of clobazam and will be monitored for a period of fo...
What is the current status of trial NCT03371836?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2017-10-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03371836?
The interventions under investigation include: Clobazam (DRUG).
Who is sponsoring clinical trial NCT03371836?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.